Dosing and administration
ULTOMIRIS® is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive.1
healthcare professional
Before starting ULTOMIRIS® immunise your patients with appropriate vaccination.*1
ULTOMIRIS® is contraindicated in patients who are not currently vaccinated against Neisseria meningitidis unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.1 Please consult the Summary of Product Characteristics prior to prescribing.
* Vaccines against serogroups A, C, Y, W135 and B where available, are recommended in preventing the commonly pathogenic meningococcal serogroups. Patients must be vaccinated or revaccinated according to current national guidelines for vaccination use. If the patient is being switched from eculizumab treatment, physicians should verify that meningococcal vaccination is current according to national guidelines for vaccination use.1
- Vaccination may not be sufficient to prevent meningococcal infection1
- Consideration should be given to official guidance on the appropriate use of antibacterial agents1
- Cases of serious meningococcal infections/sepsis have been reported in patients treated with ULTOMIRIS®1
- Cases of serious or fatal meningococcal infections/sepsis have been reported in patients treated with other terminal complement inhibitors1
- All patients should be monitored for early signs of meningococcal infection and sepsis, evaluated immediately if infection is suspected, and treated with appropriate antibiotics1
- Patients should be informed of these signs and symptoms, and steps should be taken to seek medical care immediately1
- Physicians should provide patients with important safety information to minimise the risk of serious side effects: ULTOMIRIS® Patient Guide and Patient Safety Card
Please refer to the ULTOMIRIS® Summary of Product Characteristics and the package leaflet for further dosing, supplemental dosing and administration instructions
- Typical infusion lasts < 1 hour for many patients,† with monitoring for at least 1 hour after infusions for signs or symptoms of an infusion-related reaction1
- The dosing schedule is allowed to occasionally vary by ±7 days of the scheduled infusion day, except for the first maintenance dose of ULTOMIRIS®1
Discover the mechanism of action of ULTOMIRIS®
*
ULTOMIRIS® must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological, renal, neuromuscular or neuroinflammatory disorders.1
†
Minimum infusion time for ULTOMIRIS® 100 mg/mL maintenance doses ranges from 30 minutes to 75 minutes, depending on body weight.1
Adverse Event Reporting
Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com
AQP4-IgG+, aquaporin-4 immunoglobulin G positive; C5, complement component 5; CNS, central nervous system; IV, intravenous; NMOSD, neuromyelitis optica spectrum disorder.